Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513622 | 0.95 | KDM4E (0.58) | KDM4ESMYD3EPHX2KDM4CNAMPT | |
| SCHEMBL8515153 | 0.92 | KDM4E (0.58) | KDM4ESMYD3EPHX2KDM4CNAMPT | |
| SCHEMBL8516388 | 0.92 | KDM4E (0.58) | KDM4ESMYD3EPHX2KDM4CNAMPT | |
| Acetone SCHEMBL28835039 | 0.92 | KDM4E (0.50) | KDM4EEPHX2KDM4CNAMPTNPC1 | |
| SCHEMBL13349296 | 0.87 | POLB (0.50) | KDM4EEPHX2KDM4CNAMPTHDAC1 | |
| SCHEMBL31365939 | 0.86 | L3MBTL1 (0.57) | KDM4EEPHX2NPC1RAB9AMAPT | |
| SCHEMBL16688446 | 0.86 | MAPK1 (0.61) | KDM4ENAMPTHDAC1MAPK1CYP1A2 | |
| SCHEMBL12364920 | 0.86 | EPHX2 (0.60) | KDM4EEPHX2NAMPTNPC1RAB9A | |
| SCHEMBL6417682 | 0.85 | ALDH1A1 (0.49) | KDM4ENAMPTHDAC1MAPK1 | |
| SCHEMBL14000504 | 0.85 | KDM4E (0.52) | KDM4EEPHX2KDM4CHDAC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643301-B1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PF MEDICAMENT (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2643301-B1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PF MEDICAMENT (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2643301-A1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | Pierre Fabre Medicament (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012069608-A1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069608-A1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | SLC40A1, CDC73, BRCA1 | KDM4E 4131/4885SMYD3 2645/4885EPHX2 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.